ASCOResponse rates were 100% among 15 patients with advanced
head and neck malignancies treated with a combination of radiation
therapy and C225 (cetuximab). Complete responses occurred in 13 of
the 15 evaluable patients, James Bonner, MD, reported at the 36th
Annual Meeting of the American Society of Clinical Oncology (ASCO) in
C225 is an anti-EGFr (epidermal growth factor receptor) chimeric
monoclonal antibody (MoAb) being investigated by ImClone Systems Inc.
The antibody was originally developed by Dr. John Mendelsohn at
Memorial Sloan-Kettering Cancer Center.
While preclinical experience has shown 10 Gy radiation to have very
little effect on xenografts in animals, C225 produced a marked
decrement in growth. Combining radiation with C225 produced complete
eradication, said Dr. Bonner, of the University of Alabama at
We thought this combination of treatments might be very
exciting in squamous cell carcinomas originating in the head and
neck, because the majority of these tumors overexpress the epidermal
growth factor receptor, he stated.
Current treatment, he said, includes surgical resection with
postoperative radiation, or radiation alone, which offers the
advantage of sparing organ function and reserving surgery for
salvage. Radiation with chemotherapy or investigational agents may
also be offered.
Radiation alone is often considered the standard initial treatment.
Complete response rates with radiation alone, however, are very low
at 25% to 35% in unresectable and 45% to 65% in resectable tumors. In
addition, locoregional control rates at 1 to 2 years are 15% to 35%
for unresectable and 25% to 45% for resectable tumors, Dr. Bonner noted.
Phase Ib/IIa Trial
The University of Alabama investigators initiated a phase Ib/IIa
trial of the C225/radiation combination in an effort to increase cell
death by damaging tumor cells, blocking cell cycle transgression, and
inhibiting tumor cells ability to facilitate DNA repair.
Patients received standard radiation therapy for 7 weeks. C225
injections were given weekly and began 1 week prior to radiation
therapy, for a total of eight injections.
In this dose-escalation study, five treatment groups with three
patients in each group received loading doses of C225 ranging from
100 mg/m² to 500 mg/m². Weekly maintenance doses ranged
from 100 mg/m² to 250 mg/m².
Patients had histologically confirmed unresectable squamous cell
carcinoma (stage III or IV), no prior radiation or chemotherapy, and
no prior monoclonal antibody therapy.
Sixteen patients entered the study, and 14 were assessed for
epidermal growth factor status. All of these patients expressed
growth factor, and half had a rating of 3+ on a scale of 0 to 3+.
Thirteen had stage IV disease, and three had stage III disease.
Thirteen of 15 evaluable patients had a complete response to therapy
(87%), and 2 had a partial response, for a 100% major response rate.
That was very encouraging for us, Dr. Bonner said.
He reported also that six patients failed locoregional control and
subsequently died. Nine, however, are living without evidence of
disease, for a 2-year actuarial survival rate of about 60%.
Dr. Bonner reported that adverse events were very similar to what one
might expect with an aggressive radiation-alone regimen. They
included stomatitis, xerostomia, and mucositis, with one grade 4
mucositis, and one grade 4 allergic response to C225. Several
patients had grade 3 mucositis.
The unique side effect of C225 is skin toxicity, a dose-dependent
follicular rash over the facial and upper thoracic regions. Almost
all patients (88%) developed some rash. Empiric therapy may or may
not be useful for the rash, Dr. Bonner noted. The rash, he pointed
out, does not interfere with the delivery of radiation to the head
and neck region and resolves in about 3 to 4 weeks after cessation of
treatment without scarring.
In summary, Dr. Bonner stated, this regimen
produced an acceptable safety profile with non-dose-limiting
toxicities consisting primarily of a follicular rash, which did not
interfere with the delivery of radiation.
He stated further that the mean duration of response was 16.9 months.
So it is a durable responsenine patients were responding
at greater than 1.5 years, and seven were in complete remission at
more than 2 years.
Based on these results, the researchers felt that a phase III trial
was warranted, and one is currently ongoing, Dr. Bonner said. The
trial will enroll about 400 patients who will be randomized to
receive standard radiation treatment alone or with weekly C225. The
trial will be conducted at the University of Alabama at Birmingham as
well as other cancer centers in the United States and Europe.